BioConnect AG advised on € 4.7 million financing round for Sloning BioTechnology GmbH
Munich-Puchheim–based Synthetic Biology company Sloning BioTechnology GmbH (“Sloning”) secured a EUR 4.7 million Series E financing round. LBBW Venture Capital GmbH, Stuttgart, joined the existing financing syndicate that includes HBM BioVentures, Zurich, KfW Bankengruppe and DEWB AG, Jena, who also supported this round.
Sloning will use the proceeds of this private placement to increase the capacities of its fully automated gene synthesis platform – SlonomicsTM – and furthermore accelerate the expansion of its gene variant library business SlonoMaxTM – The Intelligent Library. SlonoMaxTM offers a large variety of gene mutant combinations and has the potential to become the key enabling technology for protein engineering customers.
This private placement for Sloning represents BioConnect’s fourth successful transaction in 2007. Bioconnect, which belongs within the Corporate Finance Partners Group, thereby further strengthened its market position as a leading Corporate Finance firm in the European Life Sciences sector.
BioConnect acted as exclusive financial advisor to Sloning BioTechnology in this transaction.
«back
Sloning will use the proceeds of this private placement to increase the capacities of its fully automated gene synthesis platform – SlonomicsTM – and furthermore accelerate the expansion of its gene variant library business SlonoMaxTM – The Intelligent Library. SlonoMaxTM offers a large variety of gene mutant combinations and has the potential to become the key enabling technology for protein engineering customers.
This private placement for Sloning represents BioConnect’s fourth successful transaction in 2007. Bioconnect, which belongs within the Corporate Finance Partners Group, thereby further strengthened its market position as a leading Corporate Finance firm in the European Life Sciences sector.
BioConnect acted as exclusive financial advisor to Sloning BioTechnology in this transaction.
